PMID: 8944206Nov 1, 1996Paper

New treatments for patients with type 2 diabetes mellitus

Postgraduate Medical Journal
B H Wolffenbuttel, M B Graal

Abstract

In subjects with type 2 diabetes, both defects of insulin secretion and insulin resistance contribute to the development of hyperglycaemia. The major goals of treatment are to optimise blood glucose control, and normalise the associated lipid disturbances and elevated blood pressure. Pharmacologic treatment is often necessary. This paper discusses new forms of oral treatment for subjects with type 2 diabetes. These include a new sulphonylurea compound glimepiride (Amaryl), which binds to a different protein of the putative sulphonylurea receptor than glibenclamide, and seems to have a lower risk of hypoglycaemia. A new class of drugs with insulin secretory capacity, of which repaglinide (NovoNorm) is the leading compound, is now in phase III clinical trials. Alpha-glucosidase inhibitors reversibly inhibit alpha-glucosidase enzymes in the small intestine, which delays cleavage of oligo- and disaccharides to monosaccharides. This leads to a delayed and reduced blood glucose rise after a meal. Two compounds are in development or have been marketed, ie, miglitol and acarbose (Glucobay). Another new class of drugs is the thiazolidine-diones, which seem to work by enhancing insulin action. The 'insulin sensitising' effects of the lea...Continue Reading

References

Apr 1, 1992·Diabetes Care·P J KingmaA C Nieuwenhuijzen Kruseman
Aug 1, 1992·Diabetes Care·C A Hofmann, J R Colca
Jun 1, 1992·Diabetes Care·L C Groop
Jun 1, 1990·Diabetes Care·R W Stout
Nov 2, 1989·The New England Journal of Medicine·J E Gerich
Apr 1, 1988·Diabetic Medicine : a Journal of the British Diabetic Association·K G Alberti, F A Gries
Dec 31, 1994·Diabetes Research and Clinical Practice·J TuomilehtoA Aro
Oct 1, 1994·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·G GrudenG Pagano
Nov 3, 1994·The New England Journal of Medicine·J J NolanJ Olefsky
Nov 11, 1994·Journal of Medicinal Chemistry·B C CantelloP L Thurlby
Jan 1, 1993·European Journal of Clinical Pharmacology·B H WolffenbuttelA C Kruseman
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Aug 1, 1995·Diabetes Research and Clinical Practice·R C Turner, R R Holman
Aug 1, 1995·Diabetes Research and Clinical Practice·R G Josse
Oct 1, 1996·British Journal of Clinical Pharmacology·J P SelsA C Nieuwenhuijzen Kruseman
Mar 1, 1995·American Journal of Therapeutics·Donald B. HunninghakeThomas H. Oliphant
Jul 1, 1994·European Child & Adolescent Psychiatry·Maria Råstam

❮ Previous
Next ❯

Citations

Mar 21, 1998·The Journal of Nutrition·M Charlton, K S Nair
Jan 10, 2002·European Journal of Pharmacology·Leonardo PaivaUbiratan Fabres Machado
Jul 6, 2000·Trends in Endocrinology and Metabolism : TEM·R Perfetti, A Ahmad
Apr 28, 2000·Diabetic Medicine : a Journal of the British Diabetic Association·I C West
Jul 28, 2001·Diabetes Technology & Therapeutics·R PerfettiS Busselen
Jan 5, 2001·Expert Opinion on Investigational Drugs·D A Greene
Apr 13, 2007·Experimental Cell Research·Viola DenningerMichael Duszenko
Aug 1, 1997·Biochemical and Molecular Medicine·B C FengR M Kliegman
Apr 4, 2012·Cell Transplantation·Hongjun WangLeo E Otterbein
Feb 28, 2001·Diabetes, Obesity & Metabolism·E Standl
Feb 28, 2001·Diabetes, Obesity & Metabolism·M Kobayashi
Jan 29, 2000·European Journal of Clinical Investigation·A J Van Den BerghA Heerschap
May 25, 2002·European Journal of Clinical Investigation·R N BergmanS E Kahn
Dec 22, 1999·Endocrine Reviews·T J Kieffer, J F Habener
Aug 15, 2012·Endocrine Reviews·Valentina Di GialleonardoAlberto Signore
Sep 7, 2000·European Journal of Clinical Investigation·M Puig-Domingo
Aug 28, 2021·Nutrients·Malcolm J BorgTongzhi Wu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

© 2021 Meta ULC. All rights reserved